Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Azvudine
COVID-19
Molnupiravir
Nirmatrelvir/ritonavir
Retrospective study
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 Feb 2024
09 Feb 2024
Historique:
received:
21
07
2023
accepted:
06
02
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
10
2
2024
Statut:
epublish
Résumé
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19. This retrospective cohort study included patients with mild-to-moderate COVID-19 (asymptomatic, mild, and common types) at the First Hospital of Changsha (Hunan Province, China) between March and November 2022. Eligible patients were classified into the azvudine, nirmatrelvir/ritonavir, or molnupiravir groups according to the antiviral agents they received. The outcomes were the times to nucleic acid negative conversion (NANC). This study included 157 patients treated with azvudine (n = 66), molnupiravir (n = 66), or nirmatrelvir/ritonavir (n = 25). There were no statistically significant differences in the time from diagnosis to NANC among the azvudine, molnupiravir, and nirmatrelvir/ritonavir groups [median, 9 (95% CI 9-11) vs. 11 (95% CI 10-12) vs. 9 (95% CI 8-12) days, P = 0.15], time from administration to NANC [median, 9 (95% CI 8-10) vs. 10 (95% CI 9.48-11) vs. 8.708 (95% CI 7.51-11) days, P = 0.50], or hospital stay [median, 11 (95% CI 11-13) vs. 13 (95% CI 12-14) vs. 12 (95% CI 10-14) days, P = 0.14], even after adjustment for sex, age, COVID-19 type, comorbidities, Ct level, time from diagnosis to antiviral treatment, and number of symptoms. The cumulative NANC rates in the azvudine, molnupiravir, and nirmatrelvir/ritonavir groups were 15.2%/12.3%/16.0% at day 5 (P = 0.858), 34.8%/21.5%/32.0% at day 7 (P = 0.226), 66.7%/52.3%/60.0% at 10 days (P = 0.246), and 86.4%/86.2%/80.0% at day 14 (P = 0.721). No serious adverse events were reported. Azvudine may be comparable to nirmatrelvir/ritonavir and molnupiravir in adult patients with mild-to-moderate COVID-19 regarding time to NANC, hospital stay, and AEs.
Identifiants
pubmed: 38337014
doi: 10.1038/s41598-024-53862-y
pii: 10.1038/s41598-024-53862-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3318Subventions
Organisme : Key Research & Developmenta Program of Hunan Province
ID : 2022SK2047
Organisme : Key Research & Developmenta Program of Hunan Province
ID : 2020SK3014
Organisme : Natural Science Foundation of Changsha city
ID : kq2208448
Informations de copyright
© 2024. The Author(s).
Références
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review. JAMA 324, 782–793 (2020).
doi: 10.1001/jama.2020.12839
pubmed: 32648899
World Health Organization. COVID-19 Weekly Epidemiological Update. Edition 140 published 27 April 2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---27-april-2023 . Accessed May 2, 2023. (World health Organization, Geneva, 2023).
Koelle, K., Martin, M. A., Antia, R., Lopman, B. & Dean, N. E. The changing epidemiology of SARS-CoV-2. Science 375, 1116–1121 (2022).
doi: 10.1126/science.abm4915
pubmed: 35271324
pmcid: 9009722
Rothan, H. A. & Byrareddy, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 109, 102433 (2020).
doi: 10.1016/j.jaut.2020.102433
pubmed: 32113704
pmcid: 7127067
China CDC. National Novel Coronavirus Infection Epidemic Situation. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202304/t20230429_265709.html . Accessed June 14, 20232023.
Qu, P. et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA2752. Cell Host Microbe 31, 9–17 (2023).
doi: 10.1016/j.chom.2022.11.012
pubmed: 36476380
Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279-286 e278 (2023).
doi: 10.1016/j.cell.2022.12.018
pubmed: 36580913
pmcid: 9747694
Ren, S. Y., Wang, W. B., Gao, R. D. & Zhou, A. M. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. World J. Clin. Cases 10, 1–11 (2022).
doi: 10.12998/wjcc.v10.i1.1
pubmed: 35071500
pmcid: 8727245
Niu, B., Ji, S., Zhao, S. & Lei, H. Timing and magnitude of the second wave of the COVID-19 Omicron variant—189 Countries and Territories, November 2021 to February 2023. China CDC Wkly. 5, 397–401 (2023).
doi: 10.46234/ccdcw2023.076
pubmed: 37197175
pmcid: 10184472
Consortium, W. H. O. S. T. et al. (2021) Repurposed antiviral drugs for Covid-19—Interim WHO solidarity trial results. N. Engl. J. Med. 384, 497–511.
Dryden-Peterson, S. et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system: A population-based cohort study. Ann. Intern. Med. 176, 77–84 (2023).
doi: 10.7326/M22-2141
pubmed: 36508742
Vassilopoulos, A. & Mylonakis, E. In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death. Ann. Intern. Med. 175, JC63 (2022).
doi: 10.7326/J22-0038
pubmed: 35667068
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408 (2022).
doi: 10.1056/NEJMoa2118542
pubmed: 35172054
Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520 (2022).
doi: 10.1056/NEJMoa2116044
pubmed: 34914868
Khoo, S. H. et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): A randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect. Dis. 23, 183–195 (2023).
doi: 10.1016/S1473-3099(22)00644-2
pubmed: 36272432
Butler, C. C. et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): An open-label, platform-adaptive randomised controlled trial. Lancet 401, 281–293 (2023).
doi: 10.1016/S0140-6736(22)02597-1
pubmed: 36566761
Zhang, J.-L. et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct. Target. Ther. 6, 414 (2021).
doi: 10.1038/s41392-021-00835-6
pubmed: 34873151
pmcid: 8646019
Ren, Z. et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. (Weinheim, Baden-Wurttemberg, Germany) 7, e2001435 (2020).
da Silva, R. M. et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front. Med. 10, 1143485 (2023).
doi: 10.3389/fmed.2023.1143485
Gao, Y. et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J. Infect. 86, e158–e160 (2023).
doi: 10.1016/j.jinf.2023.03.023
pubmed: 37003523
pmcid: 10062713
Petrakis, V., Rafailidis, P., Trypsianis, G., Papazoglou, D. & Panagopoulos, P. The antiviral effect of nirmatrelvir/ritonavir during COVID-19 pandemic real-world data. Viruses 15, 976 (2023).
doi: 10.3390/v15040976
pubmed: 37112956
pmcid: 10144059
Gao, Y., Liu, M., Li, Z., Xu, J., Zhang, J. & Tian, J. Molnupiravir for treatment of adults with mild or moderate COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clin. Microbiol. Infect., (2023).
Zhou, Z. et al. Clinical characteristics of older and younger patients infected with SARS-CoV-2. Aging (Albany NY) 12, 11296–11305 (2020).
doi: 10.18632/aging.103535
pubmed: 32575073
Vujcic, I. Outcomes of COVID-19 among patients with liver disease. World J. Gastroenterol. 29, 815–824 (2023).
doi: 10.3748/wjg.v29.i5.815
pubmed: 36816621
pmcid: 9932431
Przekop, D., Gruszewska, E. & Chrostek, L. Liver function in COVID-19 infection. World J. Hepatol. 13, 1909–1918 (2021).
doi: 10.4254/wjh.v13.i12.1909
pubmed: 35069997
pmcid: 8727219
Yu, D. et al. Liver injury in COVID-19: Clinical features and treatment management. Virol. J. 18, 121 (2021).
doi: 10.1186/s12985-021-01593-1
pubmed: 34108015
pmcid: 8188532
Grandvuillemin, A., Rocher, F., Valnet-Rabier, M. B., Drici, M. D. & Dautriche, A. French Pharmacovigilance, N. Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic. Therapie, (2023).
Lory, P. et al. Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic. Therapie 78, 419–425 (2022).
doi: 10.1016/j.therap.2022.10.066
pubmed: 36376122
Casalini, G., Giacomelli, A. & Antinori, S. Liver tests abnormalities with licensed antiviral drugs for COVID-19: A narrative review. Expert Opin. Drug Saf. 21, 1483–1494 (2022).
doi: 10.1080/14740338.2022.2160446
pubmed: 36597859
Painter, W. P. et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 65, 10–1128 (2021).
doi: 10.1128/AAC.02428-20
Kale, A., Shelke, V., Dagar, N., Anders, H. J. & Gaikwad, A. B. How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front. Pharmacol. 14, 1053814 (2023).
doi: 10.3389/fphar.2023.1053814
pubmed: 36843922
pmcid: 9947246
Izzedine, H., Jhaveri, K. D. & Perazella, M. A. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 97, 1297–1298 (2020).
doi: 10.1016/j.kint.2020.03.015
pubmed: 32317113
pmcid: 7271263
Sun, Y. et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: A retrospective cohort study. ClinicalMedicine 59, e101981 (2023).
doi: 10.1016/j.eclinm.2023.101981
Parums, D. V. Editorial: Rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with paxlovid and molnupiravir. Med. Sci. Monit. 28, e938532 (2022).
doi: 10.12659/MSM.938532
pubmed: 36181334
pmcid: 9536144
Anderson, A. S., Caubel, P., Rusnak, J. M. & Investigators, E.-H.T. Nirmatrelvir–ritonavir and viral load rebound in Covid-19. N. Engl. J. Med. 387, 1047–1049 (2022).
doi: 10.1056/NEJMc2205944
pubmed: 36069818
Charness, M. E. et al. Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. N. Engl. J. Med. 387, 1045–1047 (2022).
doi: 10.1056/NEJMc2206449
pubmed: 36069968
Rubin, R. From positive to negative to positive again-the mystery of why COVID-19 rebounds in some patients who take paxlovid. JAMA 327, 2380–2382 (2022).
doi: 10.1001/jama.2022.9925
pubmed: 35675094
Zhou, Z. G. et al. Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19. Signal Transduct. Target. Ther. 5, 276 (2020).
doi: 10.1038/s41392-020-00407-0
pubmed: 33235253
pmcid: 7683873